Routine flumazenil administration confounds emergence time comparisons between remimazolam and propofol: a methodological concern.

This letter to the editor identifies a critical methodological concern in a recent clinical trial by Qin et al. that compared the emergence profiles of remimazolam and propofol in pediatric anesthesia. We argue that the study's findings are confounded by a fundamental"asymmetry in interventions". The remimazolam group routinely received flumazenil for pharmacological reversal, while the propofol group emerged spontaneously via natural metabolism.